Guardian Pharmacy Services, Inc. (GRDN) AI Stock Analysis

Guardian Pharmacy Services, Inc. provides a suite of technology-enabled services to assist residents of long-term health care facilities (LTCFs) across the United States. Headquartered in Atlanta, Georgia, the company serves lower acuity LTCFs, including assisted living facilities, behavioral health facilities, and group homes, with individualized clinical, drug dispensing, and administration capabilities. Its proprietary technology includes Guardian Compass dashboards for local pharmacy planning, GuardianShield Programs for LTCFs, the Order Entry QA Analyzer rules-engine for prescription error detection, and the Medication Spend Analyzer for LTCF monthly drug expenditure tracking.

Revenue expanded from $792.1M in FY2021 to $1.45B in FY2025, posting a 5-year revenue CAGR of 14.5% through FY2025. Annual revenue growth accelerated from 7.6% in FY2021 to 14.8% in FY2022, 15.1% in FY2023, 17.4% in FY2024, and 17.9% in FY2025. After posting an operating loss with an operating margin of -5.1% and net income of -$87.3M in FY2024, profitability rebounded in FY2025 with an operating margin of 6.1% and net income of $49.2M. For the trailing twelve months ended June 30, 2026, revenue totaled $1.46B with a profit margin of 4.5%. In the latest quarter ended June 30, 2026, quarterly revenue grew 2.2% year-over-year, while quarterly earnings surged 139.8%.

As of June 30, 2026, the company held $89.8M in cash and short-term investments against total debt of $35.2M, yielding net cash of $54.6M. Total assets stood at $443.6M with shareholders' equity of $245.6M. Liquidity is supported by a current ratio of 1.65 and a debt-to-equity ratio of 0.14. In FY2025, operating cash flow reached $100.3M, funding capital expenditures of $19.6M to generate free cash flow of $80.7M, while share buybacks totaled $29.0M.

At a market cap of $2.50B and an enterprise value of $2.69B, GRDN trades at a trailing P/E of 38.3x and a forward P/E of 30.2x, both above the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its EV to EBITDA ratio is 22.4x compared to the peer median of 12.0x, though its price to sales ratio of 1.7x sits below the peer median of 4.1x. Over the past year, the stock returned 62.0%, outperforming the S&P 500 (SPY) return of 16.8%.

Wall Street coverage consists of 6 Strong Buy ratings, 1 Buy rating, and zero Hold, Sell, or Strong Sell ratings. The mean price target is $49.86, representing upside of 26.3% over the last close of $39.47. For the fiscal year ending December 31, 2026, analysts estimate EPS of $1.30 (growth of 21.6%) on revenue of $1.44B. GRDN has beaten EPS estimates in 3 of the last 4 quarters, with the next earnings date scheduled for November 9, 2026.

This page is an AI-written research summary of Guardian Pharmacy Services, Inc. (GRDN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GRDN income statement, GRDN balance sheet, GRDN key metrics, GRDN analyst forecast, GRDN chart. See the GRDN stock overview for the latest quote and news.